Plate Nº 37 · recorded November 17, 2026
Health & Medicine ResearchReported finding
Kratom's Engineered Derivatives Are Sending Users to the Hospital
U.S. kratom exposures jumped from 258 in 2015 to 3,434 in 2025. Lab-boosted derivatives up to 40 times stronger than the plant now fill mislabeled products sold nationwide.
By Priya Raman5 min read998 words
In brief
- U.S. poison centers documented 3,434 kratom-related exposures in 2025, up 1,200 percent from 258 in 2015.
- A 2026 analysis found 85 percent of 44 tested kratom products did not match their labels.
- 7-OH binds to mu opioid receptors ten times more strongly than mitragynine; MGM-15 is four times stronger than 7-OH.
- In July 2026 the DEA temporarily scheduled 7-OH, MGPI, MGM-15 and MGM-16 as Schedule I drugs.
- A 2026 survey estimated about 5 million Americans have used kratom or similar products.

Kratom-related poison exposures in the United States rose 1,200 percent between 2015 and 2025, and a 2026 survey estimates that about 5 million Americans have used kratom or similar products. Behind those numbers stands a quiet chemical escalation: products sold under the plant's name increasingly contain laboratory-boosted derivatives far stronger than the opioids some users hoped to avoid.
At the University of Kansas Health System hospital in Kansas City, addiction specialist Roopa Sethi has watched the shift arrive patient by patient over the past few years. They present with what looks like severe opioid withdrawal: nausea, vomiting, muscle aches, extreme anxiety and sometimes hallucinations. Yet they have not taken fentanyl or heroin. Instead, they have used something labeled as kratom — which, testing sometimes shows, may not contain kratom at all.
"I see less fentanyl and more kratom at this point, or more 7-OH," Sethi said.
What is kratom, and how does it work?
Kratom comes from the dried leaves of Mitragyna speciosa, a tree native to Southeast Asia. Dutch scientist Pieter Willem Korthals first described it in 1839, but people in Thailand, Indonesia and Myanmar had likely used it for centuries before. "Wherever there is a stream, these trees are growing there," said Oliver Grundmann, a pharmacologist at the University of Florida in Gainesville. People chewed the leaves as a stimulant and brewed them into tea to treat pain.
In the United States, kratom is marketed as a pain treatment more "natural" than opiates such as morphine, and some people take it to ease opioid cravings or withdrawal. "When you take this product at low doses, it is used for waking up … but at higher doses it becomes opiate-like," Sethi said.
The leaf contains more than 40 naturally occurring chemicals called alkaloids (nitrogen-containing compounds that can affect the nervous system). The most important is mitragynine, which accounts for two-thirds of the plant's alkaloid content.
Mitragynine acts on the body's mu opioid receptors — molecular docking sites in the brain, spinal cord and gut that normally respond to the body's own signals, such as endorphins, and trigger pain relief and dopamine release. The receptors take their name from opium, the most famous drug that binds them. Mitragynine is unrelated to opium or morphine, and it binds only partially.
"It's kind of like a dimmer switch versus turning on the lights," said Mallory Pullman, a clinical toxicologist at the Mississippi Poison Control Center. "You don't fully light your room."
Mitragynine also engages receptors for norepinephrine, serotonin and dopamine. The activity at adrenergic receptors (the ones that respond to stress-signaling chemicals) produces a stimulant effect, so the plant delivers stimulation and sedation in turn.
Why do labels so often lie?
As the leaf dries, small amounts of mitragynine convert into another alkaloid, 7-hydroxymitragynine, or 7-OH. The body performs the same conversion after someone takes kratom. That small chemical change transforms a partial binder into a full one, locking onto mu opioid receptors the way morphine does. 7-OH binds ten times more strongly to those receptors than mitragynine, with correspondingly greater potency and addictive potential.
In plain leaves, 7-OH stays at trace levels. By the mid-2010s, however, scientists found commercial products carrying more than 500 percent more 7-OH than the plant alone contains. Today consumers can buy products labeled as pure 7-OH — and toxicologists are also finding synthetic derivatives that are stronger still. One, sold as a "research chemical" under the name MGM-15, is four times more powerful than 7-OH.
The mismatch between label and contents is widespread. In a 2026 analysis of 44 kratom products — tablets, dissolvable films and edibles — Pullman and her colleagues found that 85 percent contained something other than what the label claimed. Some advertised kratom but held very high levels of 7-OH; others contained alkaloids not listed at all.
It is "very concerning at a consumer level if you can't trust what's actually on the label," Pullman said.
How severe are the risks?
Sethi first heard the word kratom about ten years ago from patients using it to stay off opioids. They reported no addiction to the plant. The picture has changed. Patients who started with kratom or 7-OH to quit opioids "now are having really bad withdrawal and cravings and ending up in the hospital," she said. Some now seek addiction treatment not for opioids but for kratom and 7-OH themselves.
The U.S. National Poison Data System recorded just 258 kratom exposures in 2015. In 2025, U.S. poison centers documented 3,434 kratom-related exposure reports, from both callers and medical professionals.
What have regulators done?
In July 2026, the U.S. Drug Enforcement Administration temporarily classified several kratom derivatives as Schedule I drugs, a category reserved for substances with high abuse potential and no accepted medical use. The list covers:
- 7-OH, at any dose higher than that found naturally in the kratom plant
- Mitragynine pseudoindoxyl, or MGPI, a related derivative
- MGM-15 and its powerful sibling MGM-16, whose temporary scheduling was renewed in October
The U.S. Food and Drug Administration has separately warned consumers not to use these products. None of these measures affect the legality of the kratom leaf itself.
State law is a patchwork: 26 states do not regulate kratom at all, six states and the District of Columbia classify its ingredients as Schedule I controlled substances, and 18 states regulate sale and manufacture in some way.
Regulators face a familiar squeeze. "There's risk with everything," Pullman said. "I think it's important to distinguish the difference between a synthetic product versus the natural, and that way we can clearly attribute where the risk lies." When one derivative gets banned, another tends to appear in its place — a cycle that mirrors the evolution of synthetic opioids.
The plant in the stream is not the product on the gas-station shelf.
via sciencenews.org (Source)
More from Priya Raman
Show full bio
Senior reporter covering people, launches and day-to-day practice in general science news at SciBeat.
476 articles
Nearby plates
- A Federal Crackdown on 7-OH Kratom Products Could Land as Soon as November 13
- Cychlorphine: A New Opioid Up to 10 Times Stronger Than Fentanyl
- Toad Venom Psychedemic Nasal Spray Eases Depression for Eight Weeks
- Veterinary Sedative Medetomidine Is Driving a Wave of Severe Withdrawal
- Quaaludes Are Creeping Back—And This Time Nobody Knows What's In Them